Outcome measures for central nervous system symptoms in myotonic dystrophy type 1: insights from a case-controlled study

被引：0
|
作者：
Hamilton, M. J. [1 ,2 ]
McLean, J. [3 ]
Cumming, S. [2 ]
Ballantyne, B. [1 ]
McGhie, J. [2 ]
Jampana, R. [3 ]
Longman, C. [1 ]
Evans, J. J.
Monckton, D. G. [2 ]
Farrugia, M. E.
机构：
[1] Queen Elizabeth Univ Hosp, West Scotland Clin Genet Serv, Glasgow G51 4TF, Lanark, Scotland
[2] Univ Glasgow, Coll Med Vet & Life Sci, Inst Mol Cell & Syst Biol, Glasgow G12 8QQ, Lanark, Scotland
[3] Queen Elizabeth Univ Hosp, Inst Neurol Sci, Dept Neuroradiol, Glasgow G51 4TF, Lanark, Scotland
来源：
NEUROMUSCULAR DISORDERS | 2018年 / 28卷
关键词：
D O I：
10.1016/S0960-8966(18)30321-3
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
D18
引用
收藏
页码：S11 / S11
页数：1
相关论文
共 50 条
  • [21] Shedding light on motor premanifest myotonic dystrophy type 1: A molecular, muscular and central nervous system follow-up study
    Garmendia, Joana
    Labayru, Garazi
    Zulaica, Miren
    Villanua, Jorge
    Lopez de Munain, Adolfo
    Sistiaga, Andone
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 (01) : 215 - 223
  • [22] Cerebrospinal fluid markers of central nervous system injury in decompression illness - a case-controlled pilot study
    Shahim, Pashtun
    Arnell, Per
    Kvarnstroem, Andreas
    Rosen, Anders
    Bremell, Daniel
    Hagberg, Lars
    Blennow, Kaj
    Zetterberg, Henrik
    DIVING AND HYPERBARIC MEDICINE, 2015, 45 (04) : 240 - 243
  • [23] Functional MRI changes in the central motor system in myotonic dystrophy type 1
    Caramia, Francesca
    Mainero, Caterina
    Gragnani, Francesca
    Tinelli, Emanuele
    Fiorelli, Marco
    Ceschin, Vanessa
    Pantano, Patrizia
    Bucci, Elisabetta
    Barra, Veronica
    Bozzao, Luigi
    Antonini, Giovanni
    MAGNETIC RESONANCE IMAGING, 2010, 28 (02) : 226 - 234
  • [24] REVIEW OF PATIENT-REPORTED OUTCOME MEASURES FOR USE IN MYOTONIC DYSTROPHY TYPE 1 PATIENTS
    Symonds, Tara
    Randall, Jason A.
    Campbell, Patrick
    MUSCLE & NERVE, 2017, 56 (01) : 86 - 92
  • [25] Responsiveness of outcome measures in myotonic dystrophy type 1 (vol 7, pg 1382, 2020)
    Knak, K. L.
    Sheikh, A. M.
    Witting, N.
    Vissing, J.
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2021, 8 (10): : 2105 - 2105
  • [26] Getting ready for clinical trials in myotonic dystrophy type 1 with the validation of functional outcome measures
    Jimenez-Moreno, A.
    Nikolenko, N.
    Moat, D.
    Mayhew, A.
    Massey, C.
    Gorman, G.
    Newman, J.
    Kierkegaard, M.
    Atalaia, A.
    Turner, C.
    Lochmuller, H.
    NEUROMUSCULAR DISORDERS, 2017, 27 : S180 - S180
  • [27] Brain Structure and Function in Myotonic Dystrophy Type 1 (DM1): A Potential Biomarker for Disease Progression in the Central Nervous System
    DeVolder, Ian
    Magnotta, Vincent
    Gutmann, Laurie
    Nopoulos, Peggy
    ANNALS OF NEUROLOGY, 2017, 82 : S107 - S107
  • [28] Evaluating EEG as an outcome measure for CNS Symptoms in myotonic dystrophy type 1: a clinical trial analysis
    Allen, S.
    Kamali, T.
    Parker, D.
    Seto, A.
    Ehrich, E.
    Wang, E.
    Sampson, J.
    NEUROMUSCULAR DISORDERS, 2024, 43
  • [29] Perceived fatigue in myotonic dystrophy type 1: a case-control study
    Stefan Winblad
    Christopher Lindberg
    BMC Neurology, 19
  • [30] Perceived fatigue in myotonic dystrophy type 1: a case-control study
    Winblad, Stefan
    Lindberg, Christopher
    BMC NEUROLOGY, 2019, 19 (1)
12345